Fondée pour résoudre un vrai problème.
Le domaine des EV a un potentiel extraordinaire. Ce qui lui a manqué, c'est l'infrastructure. Nous la construisons.
Pourquoi BioThera Solutions a-t-elle construit une plateforme de biofabrication d'EV ?
BioThera Solutions was founded to address a critical gap in the extracellular vesicle (EV/exosome) field: the absence of scalable, standardized, and reproducible manufacturing required to bring EV technologies of all kinds into real-world application. We set out to build that infrastructure as a platform, not a single product, and to lay the foundation for every application that comes after the first.
Malgré les preuves scientifiques croissantes des EV comme systèmes de livraison biologiques puissants, l'industrie a eu du mal à traduire les résultats de laboratoire en produits commercialement viables et fabriqués de manière constante. Le problème n'est pas la biologie, c'est l'infrastructure.
We are building that infrastructure, and we started where the need was most immediate. Interest in exosome-based skincare has grown quickly, driven by genuine scientific interest and consumer demand, yet the market is crowded with products making bold claims, backed by inadequate characterization, inconsistent particle concentrations, and little regulatory transparency. There is real demand, and a real absence of material that meets rigorous scientific standards.
BioThera was built to close that gap. We bring biomanufacturing expertise to a space that has been underserved by rigorous science: characterization in line with MISEV2023, measured particle concentrations, and documentation for every batch. Our research and development has produced proprietary, patent-pending technology and the capacity to manufacture at scale. For cosmetic applications, we license our technology exclusively to Vesera™, a skincare company, and produce the material it uses.
Cosmetic applications are where the platform first meets the market, and they are only the beginning. The infrastructure we are building, from manufacturing and characterization to the evidence base, is designed to carry across biological sources and applications. Our current platform uses plant-derived vesicles; as we grow, our research extends to animal-derived sources, including human stem cell-derived vesicles, and to therapeutic applications, an important focus for our team.
Build the integrated extracellular vesicle platform the field has been missing: standardized, characterized vesicles, engineered to work across biological sources, for applications that begin with cosmetics and extend well beyond them.
With cosmetic applications as our first commercial use, we are establishing the manufacturing infrastructure, characterization rigour, and evidence base that credible EV applications, including therapeutic ones, require.
To define what credible, science-led EV technology looks like, and to build the biomanufacturing backbone the extracellular vesicle field needs to mature, across every application it reaches.
We are in the early chapters of the EV era. Our ambition is to set the standard for the field by building the manufacturing foundation, characterization rigour, and evidence base that scientists, clinicians, partners, and regulators can trust.
Ce pour quoi nous nous battons
Transparence scientifique radicale
Nous ne faisons aucune affirmation que nous ne pouvons pas étayer. Chaque spécification de produit, résultat de caractérisation et statut réglementaire est communiqué avec précision. Le langage vague et l'hyperbole marketing n'ont pas leur place dans notre façon d'opérer.
Excellence sans compromis
Normes de fabrication, protocoles de caractérisation, qualité de formulation, nous appliquons la même rigueur à chaque étape, peu importe où nous en sommes dans le cycle de développement. La qualité est intégrée, pas inspectée.
Innovation
Le domaine des EV est encore jeune. L'infrastructure de fabrication nécessaire pour rendre les EV cliniquement et commercialement viables n'existe pas encore pleinement, nous la construisons. Cela exige une véritable créativité scientifique et un courage technique.
Exécution
Les idées en biotechnologie sont nombreuses. L'exécution rigoureuse et fiable est rare. Nous comblons l'écart entre le potentiel scientifique et le déploiement réel, de manière constante, dans les délais et conformément aux spécifications.
Ottawa, Ontario, Canada
BioThera Solutions a son siège social à Ottawa, en Ontario. Notre emplacement nous donne proximité aux organismes de réglementation, un écosystème de sciences de la vie en croissance, et les collaborateurs cliniques et de recherche au cœur de notre travail.
477-150 Louis-Pasteur Private Ottawa, Ontario K1N 6N5 Canada
Université d'Ottawa : Complexe STEM · Ottawa, Ontario
Company Clarification
BioThera Solutions (Canada) is an independent biotechnology firm specializing in extracellular vesicle (EV) technology. We have no affiliation with Bio-Thera Solutions, Ltd. (China), which focuses on biosimilars and antibody-drug conjugates (ADCs). Our mission is to build the integrated platform that extracellular vesicle technology requires, from research and intellectual property to manufacturing, across the sources and applications of extracellular vesicles.
BioThera Solutions travaille exclusivement avec des partenaires sélectionnés.
Nous collaborons de manière sélective avec des partenaires de recherche, cliniques et industriels lorsqu'il existe un fort alignement scientifique et stratégique.
Les demandes de partenariat sont examinées individuellement.
Se renseigner sur un partenariatESG et responsabilité
BioThera Solutions operates with environmental, social, and governance (ESG) principles built into how we work. Our current vesicles are derived from medicinal plants rather than animal or human tissue, and our biomanufacturing process is designed to be scalable and resource-efficient. We are transparent about our science and communicate clearly with clinical partners, suppliers, and the broader research community. Our governance practices are aligned with Health Canada cosmetic notification requirements, and our scientific reporting follows MISEV (Minimal Information for Studies of Extracellular Vesicles) guidelines. Sustainability and ethical conduct are part of how we build for the long term.